Contact
About Abbott
cardiovascular
MY ACCOUNT

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Family of Drug-Eluting Stents
Frequently Asked Questions

FAQ About XIENCE™ Stent

What about magnetic resonance imaging (MRI) safety with XIENCE™ Stents?2

Nonclinical testing has shown that the XIENCE Skypoint™ and XIENCE Sierra™ Stents, in single and in overlapped configurations up to 91 mm and 71 mm in length respectively, are MR conditional.  A patient with a XIENCE™ Stent can be scanned in an MR system under the following conditions:*

  • Static magnetic field of 1.5 or 3 Tesla
  • Maximum spatial gradient field of 3000 Gauss/cm (30 T/m)
  • Maximum MR system reported whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode)

Under the scan conditions defined above, XIENCE™ Stents are expected to produce a maximum temperature rise of of less than 4.8°C after 15 minutes of continuous scanning.

In non-clinical testing, the image artifact caused by the device extends approximately 6 mm from the XIENCE™ Stent when imaged with a gradient echo or spin echo pulse sequence and a 3T MRI system. It may be necessary to optimize the MRI parameters to account for the presence of XIENCE™ Stents.

Refer to the Instructions For Use (IFU) for additional information.

How does XIENCE Skypoint™ Stent differ from previous generations of XIENCE™ DES?

XIENCE Skypoint™ Stent offers these features:

  • Increased post dilatation maximum expansion to 5.75 mm for 3.5 mm and 4.0 mm diameters2
  • No shortening at post dilatation maximum at 5.75 mm3
  • Ultra-low stent profile of 0.039" allows for easier crossing of difficult lesions3
  • Best in class deliverability while expending less force across lesions3
  • XIENCE Skypoint™ Stent provides a broader size matrix with 4.5 mm, 5.0 mm stent diameters and 48 mm lengths2

The ultra-low crossing profile allows users to choose XIENCE™ Stent for the most challenging cases of coronary artery disease. XIENCE™ Stents, in addition to being the most studied stents, produce consistently low stent thrombosis (ST) rates.1


What is the dual antiplatelet therapy (DAPT) duration with XIENCE™ Stents?

With more than 30,000 XIENCE™ DES patients analysed in DAPT studies,4 Abbott has received a 1-month DAPT CE indication for High Bleeding Risk patients.2

In addition, the STOPDAPT, STOPDAPT-2, STOPDAPT-3, XIENCE 28 and XIENCE 90 trials reported consistently low ST rates when DAPT was discontinued after 1 or 3 months.4 (XIENCE 28, STOPDAPT, STOPDAPT-2 and XIENCE 90 results at 12 months). Learn more about DAPT.

Explore Abbott's technologies for your needs.

Explore Abbott's technologies for your needs.

Access personalised education and training

Access personalised education and training

How can we help? Reach Abbott’s fast support here.

How can we help? Reach Abbott’s fast support here.

* The effects of MRI on overlapped stents greater than 71 mm in length, or involving stents with fractured struts, are unknown.
 

 

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. XIENCE Skypoint™ and XIENCE Sierra™ Stent Instructions for Use (IFU). Refer to IFUs for additional information.
  3. Data on file at Abbott.
  4. Mehran R, et al. TCT Connect 2020 – XIENCE 28/90. Watanabe H, et al. JAMA. 2019;321(24):2414-2427. Hahn J, et al. ACC 2019 – SMART CHOICE. Varenne O, et al. Lancet. 2018.391:41-50 – SENIOR. Kirtane A, et al. TCT 2019 – EVOLVE Short DAPT. Kedhi E, et al. PCT eCourse 2020 – OnyxOne; Postma W, et al. Cather Cardiovasc Interv. 2020;95:706-710 – DAPT-STEMI. Valgimigli, M., et al. NEJM. 2021;10.1056. Natsuaki, M., et al. AHA. 2023;1:49:00

 

 

MAT-2413713 V1.0

POLICIES
LOGIN & REGISTRATION
Abbott logo

Information contained herein for distribution in Australia and New Zealand only.
CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.
Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise Mt Wellington, Auckland 1060 Tel: 0800 827 285
Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 939
© 2025 Abbott. All Rights Reserved.
MAT-2105201 v7.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

MAT-2105201 v1.0